- Home
- PODD vs BMRN Comparison
PODD vs BMRN Comparison
Compare PODD & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PODD | BMRN |
|---|---|---|
| Founded | 2000 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.4B |
| IPO Year | 2007 | 1999 |
Fundamental Metrics
Financial Performance| Metric | PODD | BMRN |
|---|---|---|
| Price | $158.62 | $52.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 18 |
| Target Price | ★ $341.48 | $88.22 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | 0.54 |
| Revenue | ★ $2,708,100,000.00 | $1,313,646,000.00 |
| Revenue This Year | $24.55 | $15.02 |
| Revenue Next Year | $19.18 | $12.23 |
| P/E Ratio | $118.53 | ★ $97.70 |
| Revenue Growth | ★ 30.73 | 17.62 |
| 52 Week Low | $148.31 | $50.76 |
| 52 Week High | $354.88 | $66.28 |
Technical Indicators
Market Signals| Indicator | PODD | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 33.41 | 41.37 |
| Support Level | N/A | $52.06 |
| Resistance Level | $205.95 | $56.91 |
| Average True Range (ATR) | 8.61 | 1.66 |
| MACD | -1.04 | -0.02 |
| Stochastic Oscillator | 24.16 | 7.87 |
Price Performance
Historical ComparisonAbout PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.